EUROoCS has several Working Groups (WGs) for which we are looking for enthusiastic members willing to contribute to the vision and mission of EUROoCS.
The following WGs have been set up and are open for members:
- Digital Meetings
- Dissemination & Outreach
- Technology and Science Implementation
- Teaching & Training
- Diversity & Inclusion
If you are interested to join and/or would like more information on these WGs, please contact the chair of the corresponding WG via the email address provided in the respective descriptions.
On Thursday, September 29, 2022 Senate Bill 5002, ‘FDA Modernization Act 2.0’ was both introduced in the Senate and passed by unanimous consent.
The Federal Food, Drug and Cosmetics Act (FFDCA) of 1938 mandated that all new drugs be tested in animals to protect patients from unknown toxicity. New technologies have now come to the point that they can often better protect society against unforeseen toxic effects of new medicines than animal testing. Animal models have been essential in the development of all kinds of medicines. But now it is known that a large proportion of the drugs that are safe in animals eventually fail in human trials. So on Sept. 7, representatives from several universities and companies wrote an open letter to representatives of the US Congress encouraging them to pass the FDA Modernization Act. This law provides the opportunity to use suitable alternative methods. This law has now been passed.
This bill marks a turning point in how animal testing is seen in drug development. By stating that innovative technologies such as Organs-on-Chip and microphysiological systems can be used to evaluate drug safety and efficacy, the bill enables relevant validated human models to replace animal tests. Importantly, the FDA Modernization Act doesn’t call for the immediate elimination of animal testing. Rather, it allows researchers to use the models that are most appropriate for their studies, which may often mean using microphysiological systems (MPS) instead of animals.
For more information:
FDA Modernization Act 2.0 pdf
Open Letter to the U.S. Congress
Act to end animal testing requirement passes Senate
The 3Rs science prize is granted every two years to a scientist with an outstanding contribution to 3Rs. We want to promote positive contributions from industry or academia and encourage more scientists to focus their research on the 3Rs goals. Scientists working on relevant methods for regulatory testing (e.g. safety, efficacy, batch testing) providing an outstanding contribution to the use of the 3Rs may apply for the prize.
The EPAA European Partnership for Alternatives (EPAA3Rs) 2022 3Rs Science Prize is open for submissions. For more information and how to apply see here.
Congratulations to Dr Daniel Ferreira at the Instituto de Investigação e Inovação em Saúde, Portugal who has been awarded the International 3Rs Prize for his publication in Advanced Science. Daniel and colleagues have adapted a method to enable organ-on-a-chip systems to be designed, developed and printed with commercially available equipment and materials.
Ferreira DA et al. (2021). Alternative to Soft Lithography for the Fabrication of Organ-on-a-Chip Elastomeric-Based Devices and Microactuators. Advanced Science 8:2003273. doi: 10.1002/advs.202003273